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Cellular energy metabolism is one of the main processes affected during the transition from normal to cancer cells,
and it is a crucial determinant of cell proliferation or cell death. As a support for rapid proliferation, cancer cells
choose to use glycolysis even in the presence of oxygen (Warburg effect) to fuel macromolecules for the synthesis of
nucleotides, fatty acids, and amino acids for the accelerated mitosis, rather than fuel the tricarboxylic acid cycle and
oxidative phosphorylation. Mitochondria biogenesis is also reprogrammed in cancer cells, and the destiny of those
cells is determined by the balance between energy and macromolecule supplies, and the efficiency of buffering of
the cumulative radical oxygen species. In glioblastoma, the most frequent and malignant adult brain tumor, a
metabolic shift toward aerobic glycolysis is observed, with regulation by well known genes as integrants of
oncogenic pathways such as phosphoinositide 3-kinase/protein kinase, MYC, and hypoxia regulated gene as hypoxia
induced factor 1. The expression profile of a set of genes coding for glycolysis and the tricarboxylic acid cycle in
glioblastoma cases confirms this metabolic switch. An understanding of how the main metabolic pathways are
modified by cancer cells and the interactions between oncogenes and tumor suppressor genes with these pathways
may enlighten new strategies in cancer therapy. In the present review, the main metabolic pathways are compared
in normal and cancer cells, and key regulations by the main oncogenes and tumor suppressor genes are discussed.
Potential therapeutic targets of the cancer energetic metabolism are enumerated, highlighting the astrocytomas,
the most common brain cancer.
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The incidence of primary brain tumors is estimated at 7.2–
12.5 per 100 million persons per year, representing around
2% of all adult primary tumors and 23% of cancer in
childhood. Mortality resulting from primary brain tumor
amounts to 13,000 deaths per year, which is 2% of adult and
26% of childhood cancer deaths.1–4 Astrocytoma, a brain
tumor originating in glial cell types, is the most frequent
brain tumor, and glioblastoma (GBM), the grade IV astro-
cytoma, is the most malignant and frequent of these.5 In spite
of the introduction of new molecular-based therapies, this
mortality has not changed much during the last three
decades.6–9 The survival outcome for GBM patients has
improved from 3 months following surgical resection only to
8 months with the introduction of radiotherapy10 and to 6.9
months of median progression-free survival and median
overall survival of 14.6 months with the further addition of
temozolomide concurrently with irradiation.11 Diffuse infil-
tration of tumor cells into normal brain tissue presents
difficulties in surgical resection and partially explains the
poor outcome. Furthermore, the diverse causative genotypes
leading to a heterogeneous histological phenotype are
additional characteristics of this tumor offering obstacles to
effective therapy. Recent studies demonstrating the presence
of multiple mutations in brain tumors, specifically in GBM12
and medulloblastoma,13 corroborate the hypothesis that the
development of a brain tumor also requires the acquisition of
several mutations, as described previously for colorectal
carcinoma.14 At the same time, the Cancer Genome Atlas
Research Network performed a large-scale multi-dimen-
sional analysis of the molecular characteristics of GBM and
provided a network view of the pathways altered in the
development of GBM.15 Nonetheless, cumulative evidence
shows that mutations are not the only cause of the altered
gene expression of cancer cells, and that epigenetic altera-
tions,16,17 heritable and reversible changes other than the
DNA sequences,18 and aneuploidy, numerical and structural
abnormalities in chromosomes,19 are common alterations in
tumor cells and may also modify gene expression and play a
crucial role in tumorigenesis. Epigenetic modulation of gene
expression is essential for normal cellular development, and
promoter CpG island hypermethylation and transcriptional
silencing of tumor suppressor genes and pro-differentiation
factors are hallmarks of epigenetic alteration in cancer cells.
For example, methylation of the O-6-methylguanine-DNA
methyltransferase promoter in GBM has been shown to be a
useful predictor of the responsiveness of the tumors to
alkylating agents.20–22 In addition, cellular energy metabo-
lism is one of the main processes affected during the
transition from normal to cancer cells. Metabolic activity is
a relevant determinant of a cell decision to proliferate or die.
Cancer cells alter their metabolism in order to support rapid
proliferation. Otto Warburg, Nobel Prize laureate for
Physiology Medicine in 1931, demonstrated that cancer cells
do not metabolize glucose in the same way as normal adult
differentiated cells. Cancer cells generally use glycolysis even
in the presence of abundant oxygen, a phenomenon named
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aerobic glycolysis, theWarburg effect,23,24 rather than fuel the
tricarboxylic acid (TCA) cycle. It is currently believed that the
glycolytic switch is acquired very early in tumorigenesis even
before tumors experience hypoxia.25
In the present review, the main metabolic pathways in
normal adult cells are described first, then the modifications
that occur in cancer cells are presented highlighting the
potential therapeutic targets, and finally, the interactions
between oncogenes and tumor suppressor genes with
metabolic pathways are discussed.
Metabolism in normal cells
In normal cells, to produce two viable daughter cells at
mitosis, all the cellular contents must be replicated, and
energy is necessary for this to happen. Glucose participates
in cellular energy production with two adenosine tripho-
sphate (ATP) synthesis through glycolysis and up to 36
ATPs through its complete catabolism by the TCA cycle and
OXPHOS (oxidative phosphorylation) (Figure 1). The large
requirements for nucleotides, amino acids, and lipids for the
daughter cells are provided by intermediate metabolites of
these pathways. In addition to glucose, glutamine is the
other molecule catabolized in appreciable quantities for
most mammalian cells in culture. Both molecules supply
carbon, nitrogen, free energy, and reducing equivalents
necessary to support cell growth and division. This means
that glucose, in addition to being used for ATP synthesis,
should also be diverted to macromolecular precursors such
as acetyl-CoA for fatty acids, glycolytic intermediates for
non-essential amino acids, and ribose for nucleotides to
generate biomass.
Glycolytic pathway. Glucose enters the cell through
glucose transporters (GLUTs) and, once intracellular, is pho-
sphorylated to glucose-6-phosphate (G6P) by hexokinase 2
(HK2). Phosphoglucose isomerase catalyzes G6P to fructose-
6-phosphate (F6P), which yields fructose-1,6-biphosphate by
phosphofructokinase 1 (PFK1), and then pyruvate and ATP
by pyruvate kinase (PK) in the final step of glycolysis.
Pyruvate is converted to acetyl-CoA, which enters the TCA
cycle. Ultimately, glycolysis produces two ATP molecules
and six NADHmolecules per glucose. In normal tissues, most
of the pyruvate is directed into the mitochondrion to be
converted into acetyl-CoA by the action of pyruvate
dehydrogenase (PDH) or transaminated to form alanine
(Figure 2).
Pentose phosphate pathway (PPP). This is a metabolic
pathway that generates NADP and pentose sugars from
G6P. The enzyme that governs the entry of G6P into this
pathway is glucose-6-phosphate dehydrogenase (G6PD),
which is regulated by the availability of its substrate and the
NADPH to NADP+ ratio.26 G6P is converted to ribose-5-
phosphate (R5P) while producing two molecules of
Figure 1 - Metabolic differences between normal and cancer cells. Normal cells primarily metabolize glucose to pyruvate for growth
and survival, followed by complete oxidation of pyruvate to CO2 through the TCA cycle and the OXPHOS process in the mitochondria,
generating 36 ATPs per glucose. O2 is essential once it is required as the final acceptor of electrons. When O2 is limited, pyruvate is
metabolized to lactate. Cancer cells convert most glucose to lactate regardless of the availability of O2 (the Warburg effect), diverting
glucose metabolites from energy production to anabolic process to accelerate cell proliferation, at the expense of generating only two
ATPs per glucose.
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Figure 2 -Metabolic remodeling in cancer cells and regulation by signaling pathways involving oncogenes and tumor suppressor genes.
The key enzymes of glycolysis, the TCA cycle, the pentose phosphate pathway, glutaminolysis, nucleotide, and lipid biosynthesis are
shown as the regulation points by oncogenes and tumor suppressor genes.
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NADPH. NADPH is both a major cellular antioxidant,
maintaining glutathione in a reduced state to prevent
oxidative damage, and a required cofactor in the reductive
biosynthesis of fatty acids, nucleotides, and amino acids.
NADH is also used in mitochondrial OXPHOS (Figure 2).
Tricarboxylic acid (TCA) cycle. Pyruvate produced by
glycolysis is converted to acetyl-CoA, which enters the
TCA cycle, and citrate, a-ketoglutarate, succinyl-CoA,
fumarate, malate, and oxaloacetate are produced as
intermediate products. Most of the carbon for fatty acids
derives from acetyl-CoA synthesized in the mitochondrial
matrix. However, acetyl-CoA cannot cross the inner
mitochondrial membrane, but intramitochondrial acetyl-
CoA and oxaloacetate combine to form citrate, which is
transported out of the mitochondria and broken back down
into its constituents by ATP citrate lyase (ACL). Acetyl-CoA
is converted to malonyl-CoA by acetyl-CoA carboxylase,
and acetyl-CoA and malonyl-CoA are then both used by the
multi-subunit enzyme fatty acid synthase (FAS) for the
synthesis and elongation of fatty acid chains. Oxaloacetate is
used for the synthesis of non-essential amino acids.
Cytosolic and nuclear acetyl-CoA is also a precursor for
the post-translational modification of proteins (for example,
histones) by acetylation. Similarly to citrate, malate
produced in the TCA cycle leaves the mitochondria, and it
is converted to pyruvate plus NADPH. Citrate might also be
converted to isocitrate and then to a-ketoglutarate,
generating another molecule of NADPH by the action of
isocitrate dehydrogenase 1 (IDH1). In addition to glucose,
amino acids can also fuel the TCA cycle. Glutamine supplies
carbon in the form of mitochondrial oxaloacetate to
maintain citrate production in the first step of the TCA
cycle (Figure 2).
Glutaminolysis. Glutamine contributes both to the
substrate needs of a dividing cell and to the control of
redox potentials through the synthesis of NADH. After
glutamine is taken into the cell, a mitochondrial-associated
enzyme, glutaminase-1 (GLS), converts it to glutamate.
Glutamate is converted to a-ketoglutarate and enters the
TCA cycle in the mitochondria (Figure 2). Glutamate can
also be converted to aspartate, which contributes to
nucleotide synthesis. The excessive quantity of glutamine
used by the cells results in alanine and ammonium
secretions.
Metabolic modifications in cancer cells and
potential targets for therapy
Cancer cells adapt themselves to maximize their ability to
synthesize substrates for membranes, nucleic acids, and
proteins for the increased proliferative rate, a major
characteristic of these cells. This cannot be accomplished
without large amounts of energy (ATP), which are obtained
by increasing the use of glucose and glutamine many times.
The cancer cells rely on aerobic glycolysis, the Warburg
effect,23,24 with a reduced use of the TCA cycle, so that the
pyruvate made in glycolysis is converted to lactate27
(Figure 1). In fact, the fate of pyruvate depends on many
factors, of which oxygen availability is one of the most
important. In the presence of oxygen, the pyruvate is directed
into the mitochondrion to be converted into acetyl-CoA by
the action of PDH or transaminated to form alanine. And
then, once inside the mitochondrion, pyruvate is completely
oxidized through the TCA cycle and OXPHOS. However, in
cancer cells, PDH activity is blocked by the hypoxia-driven
enzyme pyruvate dehydrogenase kinase 1 (PDK1).28,29 In
addition, an increase in lactate dehydrogenase A (LDHA)
enzymatic activity is observed in cancer cells (Figure 2).30,31
These two facts determine the fate of pyruvate, which is
converted into lactate, contributing to the Warburg effect
and to the enhancement of the malignant phenotype.32,33
Animal experiments knocking down LHDA or inhibiting
PDK1, using interference RNA or dichloroacetate, have
demonstrated a reduction in tumor growth in xenograft
models.30,31,34 Such results corroborate the importance of
the decrease in the rate of pyruvate entering the TCA cycle
and the concurrent increase in lactate production for the
growth and survival of tumor cells. The lactate produced is
exported from the cells by monocarboxylate transporter 4
(MCT4), which allows the cell to preserve normal cellular pH
(Figure 1). Oxygenated normal cells can remove lactate
from the extracellular fluid using monocarboxylate transpor-
ter 1, and convert it back to pyruvate for further oxidation,
using the lactate dehydrogenase B (LDHB) isoform.
However, the same is not observed in hypoxic cancer cells,
and the large amounts of exported lactate create an acidic
tumor environment, which encourages cancer cell invasion.
Thus, therapies targeting tumor acidification would inhibit
glycolytic energy production and may also inhibit tumor cell
invasion.35 Nevertheless, treatment regimens directed
toward such ubiquitous transporters, such as monocarbox-
ylate transporters, are also likely to affect normal tissues.
Therefore, either their action must be extremely rapid or the
dose very low to avoid side-effects in other tissues.
The pyruvate synthesis itself by PK is also an important
energy-producing step in glycolysis. This step is highly
regulated by isoform selection and by allosteric regulation.
Four PK isoforms have been described in humans: PKM1,
PKM2, PKL, and PKR. The PKM1 isoform is expressed only
in normal tissues and is incompatible with tumor growth.
This isoform is replaced by the alternative spliced form
PKM2 in highly proliferative tumor cells.36,37 PKL is found
in the liver and kidney, and PKR in erythrocytes. PKM2
oscillates between inactive dimeric and active tetrameric
forms. The formation of PKM2 tetramers is stimulated by
the glycolytic intermediate fructose-1,6-biphosphate.38 The
dimeric form of PKM2 retards pyruvate formation and
allows the accumulation of upstream glycolytic intermedi-
ates, promoting their distribution into the biosynthetic
pathways. The tetrameric form of PKM2 channels pyruvate
to lactate. Phosphotyrosine residues bind to the same
allosteric regulatory site of fructose-1,6-biphosphate, releas-
ing it.39,40 This regulation of enzyme activity may constitute
a molecular switch that diverts glucose metabolites from
energy production to anabolic processes when cells are
stimulated by certain tyrosine phosphorylated growth
factors. If an inhibitor could be designed for the tumor-
expressed PKM2 isoform, it might specifically inhibit
glycolysis in tumor cells, killing them by energy deficit. A
therapeutic strategy inhibiting the interaction between
phosphotyrosine residues and PKM2 to block the anabolic
process of tumor cells would also be an interesting avenue
to explore.
PFK1 is also a rate-limiting enzyme in glycolysis41 and
highly activated in tumor cells. PFK1 adds a second
phosphate group to F6P. One potent allosteric activator of
PFK1 is fructose-2,6-biphosphate (F2,6BP), the product of
the 6-phosphofructose-2-kinase/fructose2,6-biphosphatase
(PFKFB). PFKFBs are bifunctional enzymes that interconvert
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F6P and F2,6BP. PFK1 is normally inhibited by ATP, but
F2,6BP overrides this inhibition and enhances the glycolytic
flux, allowing tumor cells to maintain high glycolytic flux
despite the presence of physiological levels of ATP. An
isoform of PFKFB, isoenzyme 3 (PFKFB3), was recently
shown to promote proliferation through its effects on cell
cycle regulators. PFKFB3 is upregulated in tumors, and its
inhibition has been proved to decrease F2,6BP levels, which
in turn decreases PFK1 activity and glycolytic flux with
cytostatic effect (Figure 2).42
HK2 participates in the glycolytic pathway and also in
metabolite transport into and out of the mitochondrial
intermembrane space through its association with a voltage-
dependent anion channel,43 a 30 kDa pore protein inserted
in the outer mitochondrial membrane.44 Therefore, HK2 is
another potential therapeutic target. In fact, two hexokinase
inhibitors, lonidamine and glucose mimetic, 2-deoxyglu-
cose, are currently in clinical trials in combination with
other agents.45 3-Bromopyruvate is a further inhibitor of
HK2 with promising in vivo studies, but there is no current
clinical trial.46,47
The modifications in cancer cells enumerated above
permit an understanding of how these cells are urged to a
non-profitable choice of two ATP generation by aerobic
glycolysis instead of 36 ATP generation upon complete
glucose oxidation by the TCA cycle and OXPHOS. In spite
of this apparently ‘‘bad’’ choice, cancer cells continue to
exhibit high ratios of ATP/adenosine diphosphate (ADP)
and NADH/NAD+48 due to an alternative ATP production
by converting two ADPs to one ATP and one adenosine
monophosphate (AMP) catalyzed by adenylate kinases. This
not only helps to maintain a viable ATP/ADP ratio as ATP
production declines, but also to accumulate AMP, which
activates AMP-kinase and leads to the phosphorylation of
several targets to improve energy charge in cells.49
Another important reason for the cancer cells to switch to
aerobic glycolysis is to provide metabolic macromolecules
for the daughter cells. 13C-nuclear magnetic resonance
spectroscopy measurements show that 90% of glucose and
60% of glutamine are converted into lactate or alanine
by GBM cell cultures.50 Although each lactate excreted from
the cell wastes three carbons that might otherwise be
utilized for either ATP production or macromolecular
precursor biosynthesis, the tumor cells choose this method
to fasten carbon incorporation into biomass to increment
cell division velocity. Glutaminolysis also generates
reductive power required for fatty acid biosynthesis by
NADPH production via the activity of NADP+-specific
malate dehydrogenase (malic enzyme), in addition to
the fundamental role in replenishing the TCA cycle.51
Blocking the fuel through this pathway for the biomass to
tumor proliferation seems a good therapeutic strategy.
Phenylacetate is a drug that reduces the biological avail-
ability of glutamine in the blood. This reagent condenses
with the c-amino group of glutamine and is excreted into
urine. A previous report has demonstrated that phenylace-
tate inhibits the proliferation of glioma cells and promotes
their differentiation.52 However, the removal of glutamine
directly from the plasma may also increase the rate at
which the body cannibalizes its own muscles (cachexia).
Additionally, various other anti-glutaminolysis compounds
have been developed, but they were found to be toxic or
raised immune reactions.53
Cancer biomass reduction may also be achieved by
blocking fatty acid synthesis through the inhibition of
ACL, which converts acetyl-CoA to malonyl-CoA,54 and
FAS, a multifunctional protein that converts malonyl-CoA
to palmitate over multiple steps.55 Inhibition of both
enzymes, ACL and FAS, has been shown to limit tumor
cell proliferation and survival in vitro and in vivo.55,56 One
possible negative aspect of anti-FAS therapy is its effect on
food intake and body weight, as observed in treated rodents
that presented hypophagia and consequent weight loss.57
Deficiencies in two other enzymes participating in the TCA
cycle, fumarate hydratase (FUM) and succinate dehydro-
genase 1 (SUCD1), may also have a tumor suppressive effect
(Figure 2).58
Nucleotide biosynthesis has also been targeted to block
biomass production in cancer cells for several years. 5-
fluorouracil, cytarabine, and methotrexate are examples of
chemotherapeutic agents known as antimetabolites. Most of
these drugs target the final stages in the nucleotide synthetic
pathway, and therefore lack specificity, leading to nucleo-
tide shortage, incomplete DNA synthesis, and cell death
indistinctly of tumor and normal proliferating cells.59
Therefore, blocking the early stages of nucleotide biosynth-
esis such as R5P production could provide a better
therapeutic window than that shown by previous antimeta-
bolic therapies. Transketolase-like protein 1 (TKTL1), an
enzyme in the non-oxidative arm of the PPP that produces
R5P, has been found to be upregulated in several tumor
types,60 and knocking it down reduced the proliferation of
tumor cells, as well as decreasing lactate production and
resensitizing cells to reactive oxygen species (ROS)-generat-
ing compounds.61 Isolated mutations in either TKTL1 or
G6PD of PPP have no impact on cancer cell growth, as both
enzymes contribute to R5P production. However, simulta-
neous mutations in these two genes, blocking R5P synthesis,
are lethal for cancer cells in animals (Figure 2).62
Besides the alterations described above in the main
metabolic routes, side pathways of the TCA cycle are also
implicated in cancer progression. A highly prevalent
mutation in an enzyme related to metabolism was uncov-
ered in the recent high throughput mutation screening in
GBM, which highlights the importance of energetic meta-
bolism in tumor progression. This study revealed that up to
12% of the GBMs harbor the same mutation in the gene
encoding cytosolic IDH1.12,63 Monoallelic mutation in the
same residue 132 in IDH1 (IDH1R132) or the analogous
residue in the related enzyme IDH2 is a common feature of
gliomas, as more than 80% of indolent gliomas harbor such
a mutation.64,65 IDH1 and IDH2 couple the reversible
conversion of isocitrate to a-ketoglutarate and NADP+ to
NADPH. IDH1 is located in the cytosol and the peroxi-
some66,67 and produces NADPH.68 In the peroxisome,
NADPH contributes to cholesterol synthesis.69 IDH2 is
located in the mitochondria and catalyzes the isocitrate to a-
ketoglutarate reaction in the TCA cycle.70 The occurrence of
IDH1 mutations correlated with approximately twofold
diminished NADP+-dependent IDH activity, and total
NADPH production is hampered by 38% in GBM harboring
the IDH1R132 mutation. Therefore, mutated IDH1 consumes
rather than produces NADPH. NADPH/NADH is both a
major antioxidant, maintaining glutathione in a reduced
state, protecting the cell from ROS, and a required cofactor
in the biosynthesis of fatty acids, nucleotides, and amino
acids. Thus, the NADPH level may affect not only cellular
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proliferation but also mutation rates.71 Then, the low
NADPH levels due to IDH1R132 mutation in GBM may
sensitize tumors to irradiation and chemotherapy.72 In
contrast, IDH1R132 mutation also leads to the accumulation
of 2-hydroxyglutarate which, based on its structural
similarity to a-ketoglutarate, may competitively inhibit
prolyl hydroxylase, which targets hypoxia induced factor
1-a (HIF-1a) for ubiquitylation and subsequent proteasomal
degradation. Therefore, the substrate of the IDH1R132
mutation stabilizes HIF-1a, which activates metabolic
changes, as described below, and stimulates invasion, cell
survival, and angiogenesis (Figure 2).73, 74
An important penalty for this increased flux of macro-
molecules to provide biomass for the proliferating cancer
cells not converted to aerobic glycolysis is also an increase
in mitochondrial OXPHOS, the major source of ROS
production. Elevated mitochondrial ROS formation fre-
quently occurs upon suppression of pyruvate input into
OXPHOS.75 This is justified only when additional blockage
exists within the electron transport chain, such as that
caused by mutations or an insufficiency of mitochondria-
encoded subunits, or HIF-1 and oncogene-mediated sup-
pression of electron transport chain components. Slow
electron transport at a relatively high substrate also
pressures the electron transport chain with a consequent
increase in ROS production. This high-level ROS generation
promotes genetic instability in tumors, favors growth,
chemotherapeutic escape, and evasion of senescence, all
contributing to the increase in tumor malignancy. Therefore,
the mitochondrion, where ROS is mainly produced, seems
to play an important role in the tumorigenic phenotype.76
The mitochondrial DNA (mtDNA) encodes 13 of the
electron transport chain proteins, and consequently, altera-
tions in these coding genes lead to OXPHOS malfunction
and inability to synthesize ATP and to reduce oxygen,
which generates ROS. In the past decade, a wide spectrum
of mutations in mtDNA has been identified in human
cancers,77,78 including depletion of mtDNA. The lower
content of copy numbers of mtDNA was associated with
higher tumor malignancy among astrocytomas.79 Further
analysis of mitochondrial genome and mitochondria bio-
genesis in different tumors may offer new insights for
cancer therapy.
There are several ways to lower ROS levels, with
glutathione being the major molecule involved, which
eliminates ROS by accepting an electron and converting
to its oxidized form glutathione disulfide. The enzyme
glutathione reductase uses NADPH to reduce glutathione
disulfide to glutathione. Low levels of glutathione/glu-
tathione disulfide have been demonstrated in highly
proliferative glioma samples.80 Thus, therapeutic targets to
control ROS levels can also be exploited to selectively kill
cancer cells.
Considering the current knowledge about cancer metabo-
lism, it seems theoretically reasonable to target metabolic
pathways for the control of cancer progression. However, no
significant effect on tumor growth has been observed when
the targets were applied as monotherapy.81,82 Nevertheless,
these drugs have been proved to sensitize tumors to other
chemotherapeutic agents (such as paclitaxel),83 presumably
through reducing ATP levels. Then, new inhibitors of the
glycolytic pathway have been used in combination with both
chemotherapy and radiotherapy, in Phase II and III clinical
trials against breast, ovarian, lung cancers,84-86 and GBM45
and the outcome of these trials may permit a better under-
standing of the metabolic impact on tumorigenesis.
Specifically targeting the tumor cells and not normal
proliferating cells continues to be an issue with this
antimetabolic strategy for cancer control, as with most other
chemotherapies. Targeting tumor-specific enzyme isoforms,
suppressing the activity of an enzyme, or modifying the
concentration of a substrate instead of completely abolishing
it might provide a strategy to attack mainly tumor cells.
Interestingly, the drugs developed to target metabolic
diseases may also be applied in oncotherapy. Metformin,
an oral hypoglycemic agent widely used to treat diabetes, is
such an example.87,88 A number of retrospective clinical
studies have found that metformin may offer a possible
benefit in cancer prevention as well as in outcome when used
with other cancer therapies.89 Similarly, an interesting
premise is to bypass glycolysis through diet modification.
The ketogenic diet with low carbohydrate and high fat,
specifically medium-chain triglycerides, relies on the con-
sumption of food that does not increase plasma glucose, but
produces ketone bodies as a carbon source for energy
production. Tumor cells depending on high glycolytic flux
are not expected to survive on this alternative fuel source.90,91
Although this type of diet is not likely to be applied as a
monotherapy, it may well prove to be useful to reinforce
other antimetabolic therapies.
Recently, it was proposed that several ‘‘waves’’ of gene
expression reprogramming occur during carcinogenesis,
starting with oncogene-mediated alterations, followed by
HIF-mediated expression, resulting in increased aerobic
glycolysis and suppression of mitochondrial biogenesis.
Then, on account of a high proliferation rate leading to
nutrient shortage, there would be a third ‘‘wave’’ of
adaptation with enhanced glutaminolysis. A retrograde
signaling from revitalized mitochondria might constitute a
fourth ‘‘wave’’.92 Most probably, these proposed waves may
occur simultaneously in a heterogeneous solid tumor, where
hypoxic areas coexist with oxygenated areas, leading to a
distinct pool of cells with different metabolic characteristics.
In fact, the results produced by our group in a series
of primary GBM corroborate this heterogeneity.93,94
Concerning the metabolic profile of these GBM, the
oligonucleotide microarray data have shown that all the
key enzymes in the glycolytic pathway were not hyper-
expressed and nor were the TCA cycle enzymes hypoex-
pressed. Figure 3 shows the mean normalized fluorescence
of these key enzymes genes of three different samples of
non-tumoral brain tissues and GBM. Concomitantly, deple-
tion of the mitochondrial DNA with overexpression of the
mitochondrial transcription factor A was observed, not
following the theoretical model, confirming the complexity
of mitochondrial biogenesis reprogramming.79 These pre-
liminary results confirm the complexity of metabolism
regulation of a tumor composed of pools of cells in different
stages of metabolic reprogramming. Therefore, most prob-
ably, a better outcome for the cancer patient may be
achieved by the better dynamic combination of targeted
therapies.
Moreover, these metabolic modifications should be
contextualized in oncogene/tumor suppressor gene path-
ways already known. From the metabolic view, an
oncogenic pathway will provide autonomous nutrient
uptake and a proliferative metabolism program, in
contrast to a suppressor pathway, which will prevent
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nutrient utilization for anabolic processes. Development
of future therapies might also fit in this model, targe-
ting self-limiting steps of nutrient production and
metabolism.25,95
Oncogenes and tumor suppressor genes
participating in the metabolic switch
Oncogenes. The phosphoinositide 3-kinase (PI3K)
signaling pathway is one of the major pathways linked to the
development of several tumors, including primary GBM.96,97
PI3K is recruited to the cellular membrane through the
activation of epidermal growth factor receptor (EGFR), and it
is phosphorylated from phosphatidylinositol-4,5-biphosphate
to 3-phosphate, which activates target molecules such as
protein kinase b (AKT) and mammalian target of rapamycin
(mTOR), which induces cell proliferation and cell survival by
blocking apoptosis. Several molecular participants in this
pathway, such as EGFR, PTEN, and PIK3CA, present
alterations in GBM.98
The PI3K/AKT pathway may regulate glucose metabo-
lism by: (1) regulating glucose transporter expression
through AKT, which directly stimulates transcription of
the GLUT1;99 (2) enhancing glucose capture by HK2 and
inducing aerobic glycolysis by promoting HK2 binding to
voltage-dependent anion channels;100 and (3) stimulating
PFK1 activity50 (Figure 2). In addition, activation of the PI3K
pathway renders cells dependent on high levels of glucose
flux.101 Small molecules inhibiting the PI3K pathway lead to
decreased glucose uptake and correlate with tumor regres-
sion;102 response to therapy has been predicted by the
ability to disrupt glucose metabolism measured by 18F-
deoxyglucose positron emission tomography.103
Figure 3 - Oligonucleotide microarray data of genes coding for key enzymes or subunits of enzymatic complexes of glycolysis and the
TCA cycle. Three samples of non-tumoral brain tissues (blue bars) and three samples of GBM (red bars) were submitted to extraction of
total RNA and microarray analysis, as described previously.94,146 LDHA and PKM2, both enzymes of glycolysis, are upregulated in GBM,
whereas the variability in the expression profile of TCA cycle genes suggests that this cycle is uncoupled. The bars represent the median
values of the three samples. Numbers represent the normalized fluorescence. Genes coding for glycolysis enzymes: HK2, hexokinase 2;
PFK1, phosphofructokinase; PGAM1 and PGAM2, phosphoglycerate mutase 1 and 2, subunits of PGM dimer; PKM2, pyruvate kinase
M2; LDHA, lactate dehydrogenase A. Genes coding for the TCA cycle enzymes: PDHA1 and PDHA2, pyruvate dehydrogenase alpha 1
and 2; PDHB, pyruvate dehydrogenase beta; DLAT, dihydrolipoamide-acetyltransferase; DLT, dihydrolipoamide dehydrogenase; PDHX,
pyruvate dehydrogenase complex, component X, all six subunits of the enzymatic complex PDH; IDH2, isocitrate dehydrogenase 2;
SDHA, SDHB, SDHC, and SDHD, SDH complex, subunits A, B, C, and D; and FUM, fumarate hydratase.
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AKT is activated when tumor cells need metabolic
intermediates for rapid proliferation, and it promotes a
glycolytic switch under normoxic conditions without
affecting the rate of OXPHOS. Thus, cancer cells turn out
to be dependent on aerobic glycolysis for their growth and
survival under AKT-mediated metabolic influence; conse-
quently, activated AKT tumor cells undergo rapid cell death
when shifted to low-dose glucose conditions.104
HIF-1 is a pleiotropic hypoxia induced transcription
factor with a heterodimeric structure composed of HIF-1a
as the oxygen responsive subunit and HIF-1b as the
constitutively expressed subunit.105 Hypoxia is a common
microenvironment feature of solid tumors, leading to HIF-1
upregulation and consequently inducing a metabolic
switch. HIF-1 target genes are involved in glucose and
energy metabolism,106 including all glycolytic enzyme genes
except phosphoglycerate mutase (PGM).107,108 Additionally,
HIF-1 upregulates LDHA;109 PFK1, through activation of
PFKFB3,110,111 switches the isoform PKM1 to PKM2112 and
activates PDK1, which in turn inhibits PDH, reducing the
TCA cycle.113 HIF also regulates the uptake of glucose
through GLUT1 (Figure 2).114
MYC regulates a broad spectrum of genes involved in cell
cycle control, metabolism, mitochondrial function, and
regulation of apoptosis. However, the role of MYC is
complex because its ectopic expression in cancer can
concurrently drive aerobic glycolysis and/or OXPHOS
according to the tumor cell microenvironment. MYC may
trigger the expression of glycolytic genes or repress
microRNAs miR-23a/b to increase GLS and stimulate
OXPHOS through the activation of O2-dependent glutami-
nolysis (Figure 2).115 Then, MYC driven tumor cells are
particularly sensitive to glutamine withdrawal,116 and genes
involved in glutamine metabolism appear to be under both
direct and indirect transcriptional control of the MYC
protein.115,117 Glutamine depletion from MYC-transformed
cells results in the rapid loss of TCA cycle intermediates and
cell death.115 MYC also influences glycolysis by upregulat-
ing the majority of glycolytic genes, including HK2, PFK1,
LDHA, PKM2, as well as GLUT1 (Figure 2).113 Deregulated
expression of MYC collaborates with HIF-1 to confer the
glycolytic (Warburg) phenotype of tumors. Additionally,
MYC stimulates mitochondrial biogenesis in both normal
and immortalized cells.118
Suppressor genes. Tumor suppressor pathways can also
regulate cellular metabolism and may act to coordinate
nutrient utilization with cell physiology.
TP53 is by far the most well known tumor suppressor
gene. Inactivation of TP53 is observed in more than 50
different types of human cancer,119 and more than 27,000
mutations were enumerated in the International Agency for
Research on Cancer – TP53 Mutation Database (http://
www-p53.iarc.fr/). TP53 encodes a nuclear phosphoprotein
of 53 kDa, responsible for genomic integrity and cell
proliferation control. p53 protein facilitates DNA repair by
blocking the cell cycle and induces apoptosis when the
DNA damage is unrepairable.120–122 TP53 mutation in
germline cells determines Li–Fraumeni syndrome charac-
terized by predisposition to multiple types of cancer,
including breast tumor, sarcoma, and central nervous
system tumors.123,124 TP53 mutations are also frequent in
secondary GBM.125–127 There are cumulative studies
demonstrating a role for p53 in controlling metabolic
genes, such as altering glucose utilization and promoting
OXPHOS, but also contributing to the induction of
apoptosis and maintaining mitochondrial health and
activity by its localization inside the organelle. The most
straightforward role of p53 in metabolism is the dampen-
ing of glycolysis, which is completely consistent with its
function as a tumor suppressor. This limitation of glyco-
lysis may occur in different ways: (1) downregulation of
expression of several glucose transporters such as GLUT1
and GLUT4 by direct transcriptional repression128 and
GLUT3 by the indirect reduction of expression through the
inhibition of nuclear factor kappa-b kinase;129 (2) ubiqui-
tination and inactivation of PGM;130 (3) lowering F2,6BP by
p53-dependent expression of the TP53-induced glycolysis
and apoptosis regulator (TIGAR).131,132 However, p53 also
promotes glycolysis by increasing HK2 and PGM expres-
sion through p53-inducible promoters.133 Additionally, the
increase in HK2 activity in concert with a decrease in PFK1
activity (resulting from TIGAR expression) would promote
the use of the PPP.134,135 p53 has also been shown to play a
role in promoting OXPHOS through the transcriptional
activation of cytochrome c oxidase 2,136 subunit I of
cytochrome c oxidase,137 and p52R2, a subunit of ribonu-
cleotide reductase138 as well as by the post-transcriptional
regulation of cytochrome oxidase 2.139 ATP is derived in
much higher proportion through OXPHOS in cells expres-
sing p53 than in cells lacking it.140 p53 also contributes to
the maintenance of mitochondrial mass and mtDNA copy
number.141,142
In addition to the complexity of tumor cell metabolic
reprogramming in a context of impulses from oncogenes
and inactivation of tumor suppressor genes, the cancer stem
cell hypothesis should also be considered to gain a more
complete understanding of tumorigenesis and for the
efficacy of cancer therapy.
Targeting cancer stem cell metabolism as a future
perspective
The cancer stem cell hypothesis proposes that cancer
derives from a small fraction of cancer cells that constitute a
self-sustaining cell reservoir, which are responsible for
reseeding tumor cells after the first therapeutic approach.
There are some preliminary data concerning the metabolism
of the stem cells, such as increased expression of PFKFB3 in
cycling cells and decreased expression in terminally
differentiated neurons.143 It has been reported that GBM
cancer stem cells share gene expression signatures with
progenitor cells in the developing forebrain,144 and prefer-
ential overexpression of genes normally enriched in
embryonic stem cells, NANOG, OCT4, SOX2, and MYC,
were activated in poorly differentiated GBM.145 Moreover, a
subpopulation of cells that carry the known progenitor cell
marker CD133 has been identified in GBM, and when the
expression profiles of CD133+ GBM cells were compared
with CD1332 cells, 16 genes, many of which had not
previously been associated with astrocytomas, were found
to be aberrantly expressed relative to corresponding non-
neoplastic brain tissue controls.146 However, the expression
profile of genes related to energy metabolism in cancer stem
cells remains to be explored.
The development of novel metabolic based drugs holds
much promise for the improvement of cancer therapy.
Metabolism and Brain Cancer
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